Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy
- Conditions
- Pancreatic Cancer
- Registration Number
- NCT03165188
- Lead Sponsor
- NewLink Genetics Corporation
- Brief Summary
This protocol (NLG0705) provides a mechanism for the 15-year follow-up period that the FDA requires for all participants in gene transfer protocols and assures that adequate follow-up can be maintained for subjects who have received at least one dose of algenpantucel-L.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 29
- Receipt of at least one dose of algenpantucel-L within the past 15 years
- Signed consent
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of subjects with adverse events. Up to 15 years Survival Up to 15 years
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (15)
Cedars-Sinai Medical Center
🇺🇸Los Angeles, California, United States
Northwestern University
🇺🇸Chicago, Illinois, United States
NorthShore University HealthSystem
🇺🇸Evanston, Illinois, United States
Oregon Health and Science University
🇺🇸Portland, Oregon, United States
Baylor College of Medicine
🇺🇸Houston, Texas, United States
UPMC Hillman Cancer Center
🇺🇸Pittsburgh, Pennsylvania, United States
UF Health Cancer Center
🇺🇸Gainesville, Florida, United States
Stanford University Cancer Center
🇺🇸Palo Alto, California, United States
Indiana University Health Goshen Center for Cancer Care
🇺🇸Goshen, Indiana, United States
Washington University
🇺🇸Saint Louis, Missouri, United States
UT Health Cancer Center
🇺🇸San Antonio, Texas, United States
University of Wisconsin
🇺🇸Madison, Wisconsin, United States
UT Southwestern Medical Center
🇺🇸Dallas, Texas, United States
Moffitt Cancer Center
🇺🇸Tampa, Florida, United States
University of Louisville
🇺🇸Louisville, Kentucky, United States